Results 71 to 80 of about 10,425 (248)

Effect of different light‐emitting diodes on vegetative cannabis growth and antioxidant activity

JSFA reports, EarlyView.
Abstract Background Cannabis stands as one of the world's oldest plant sources for food and textile fiber. The study aimed to assess the impact of white LED (blue; 446 nm + amber; 595 nm + red; 653 nm), wide PC amber (595 nm), narrow amber (595 nm) + royal blue (430 nm) (NA + RB), and narrow amber (595 nm) + royal blue (430 nm) + cyan blue (485 nm) (NA 
Zohreh Poudineh, Philip Wiredu Addo, Vincent Desaulniers Brousseau, Anne‐Sophie Rufyikiri, Sarah MacPherson, Valérie Orsat, Mark Lefsrud   +6 more
wiley   +1 more source

The Regulatory Environment Surrounding Cannabis Medicines in the EU, the USA, and Australia

Pharmaceutics
Background/Objectives: Recent evidence supporting the medicinal use of cannabis has brought significant regulatory changes regarding its legal status, cultivation, and use.
Claudia Jardim, M. Begoña Delgado-Charro   +1 more
doaj   +1 more source

Pilot trial of THRIVE: A peer‐delivered sexual and intimate partner violence prevention program for women in substance use treatment

Journal of Traumatic Stress, EarlyView.
Abstract High rates of interpersonal violence exposure and trauma‐related mental health concerns among women in substance use treatment underscore the need for violence prevention services in these settings. Peer support specialists can play a crucial role in increasing access to trauma‐focused services and overcoming barriers, such as stigma and ...
Heidi M. Zinzow, Lauren Smalls, Irene Pericot‐Valverde, Meghan Shank, Madelyn Brancato, Greyson Chapman, Allison Smith, Caroline Greco, Kacey Eichelberger, Kimbley Smith, Alain H. Litwin   +10 more
wiley   +1 more source

History of cannabis as a medicine: a review [PDF]

Revista Brasileira de Psiquiatria, 2006
Cannabis as a medicine was used before the Christian era in Asia, mainly in India. The introduction of cannabis in the Western medicine occurred in the midst of the 19th century, reaching the climax in the last decade of that century, with the availability and usage of cannabis extracts or tinctures.
openaire   +4 more sources

Analytical Approaches to Address Challenges in the Analysis of Cannabinoids in Vascular Matrices Using Mass Spectrometry

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Phytocannabinoids are bioactive metabolites derived from the Cannabis sativa plant. They have garnered attention due to their recreational uses and therapeutic potential. Although various analytical strategies have been employed for their analysis, mass spectrometry (MS) coupled to chromatographic separation is superior due to its sensitivity ...
Radwa Mahmoud, Robert B. Laprairie, Anas El‐Aneed   +2 more
wiley   +1 more source

The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review

Frontiers in Pharmacology
IntroductionThere is growing recognition of the potential of cannabis to treat various medical conditions and symptoms, such as chronic pain, spasticity, and epilepsy.
Nadia A. Leen, Mikael A. Kowal, Albert Batalla, Matthijs G. Bossong, Matthijs G. Bossong   +4 more
doaj   +1 more source

Continuous Intrajejunal Levodopa–Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series

Movement Disorders Clinical Practice, EarlyView.
Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés, Jardel Amory, Hopes Lucie, Clément Guillemette, Lambert Laetitia, Becker Aurélie, Dexheimer Mylène, Bonnet Céline, Frismand Solène, Renaud Mathilde, Puisieux Salomé   +10 more
wiley   +1 more source

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

Movement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota, Jacy B. Parmera, Matheus Deltreggia, Pedro N. Martins, Anna Letícia M. Alves, Ananda C.M. de Falcone, Ana Rosa Santana, Maria Alice P. Falcão, Mayara A. Dias, Larissa I. Moreira, Paulo C. de Fonseca Filho, Eberval G. Figueiredo, Egberto R. Barbosa, Rubens G. Cury, Daniel C. de Andrade   +14 more
wiley   +1 more source

Cannabis Medicinal

, 2020
Este artículo presenta una pequeña revisión de la evidencia disponible acerca de las principales enfermedades para las que se propone el uso médico del cannabis.
Quiñones Laveriano, Dante M., Catacora Villasante, Manuel   +1 more
openaire   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source